<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paclitaxel (conventional): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paclitaxel (conventional): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Paclitaxel (conventional): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10946" href="/d/html/10946.html" rel="external">see "Paclitaxel (conventional): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709191"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Paclitaxel should be administered under the supervision of a health care provider experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2% to 4% of patients receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and histamine H<sub>2</sub> antagonists. Patients who experience severe hypersensitivity reactions to paclitaxel should not be rechallenged with the drug.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Paclitaxel therapy should not be given to patients with solid tumors who have baseline neutrophil counts of less than 1,500 cells/mm<sup>3</sup> or to patients with AIDS-related Kaposi sarcoma if the baseline neutrophil count is less than 1,000 cells/mm<sup>3</sup>. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving paclitaxel.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F205627"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Antineoplastic Agent, Taxane Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F205586"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The manufacturers recommend premedication with dexamethasone (20 mg orally at 12 and 6 hours prior to paclitaxel [reduce dexamethasone dose to 10 mg orally with advanced HIV disease]), diphenhydramine (50 mg IV 30 to 60 minutes prior to paclitaxel), and cimetidine or famotidine (IV 30 to 60 minutes prior to paclitaxel). Alternative premedication regimens have also been described. Refer to citations for further information.</p>
<p style="text-indent:-2em;margin-left:2em;">Data from several reports support the use of a single 10 or 20 mg IV dexamethasone dose (in combination with diphenhydramine and an H<sub>2</sub> antagonist) to prevent hypersensitivity reactions (HSR) in patients receiving paclitaxel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9261533','lexi-content-ref-34357780','lexi-content-ref-9600818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9261533','lexi-content-ref-34357780','lexi-content-ref-9600818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data from a prospective single-arm study and a retrospective analysis suggest dexamethasone may be omitted from future cycles of paclitaxel chemotherapy if no HSR occurred during the initial cycles; in the studies, patients received standard dexamethasone, diphenhydramine, and an H<sub>2</sub> antagonist premedication prior to the first 2 paclitaxel doses, and if no HSR occurred during the first 2 infusions, dexamethasone was omitted from the premedication regimen for the remaining cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34472667','lexi-content-ref-29435713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34472667','lexi-content-ref-29435713'])">Ref</a></span>). In another retrospective study, patients received the standard premedication regimen prior to the first 2 paclitaxel infusions; if no HSR occurred, all premedications were discontinued for future paclitaxel doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25519756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25519756'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="105cec0a-a7ca-40e2-861c-ca22d0bd524f">AIDS-related Kaposi sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>AIDS-related Kaposi sarcoma:</b>
<b>IV:</b> 135 mg/m<sup>2</sup> over 3 hours every 3 weeks <b>or</b> 100 mg/m<sup>2</sup> over 3 hours every 2 weeks (due to dose-related toxicity, the 100 mg/m<sup>2</sup> dose should be used for patients with a lower performance status). <b>Note:</b> Reduce the dexamethasone premedication dose to 10 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5660db6-cd1b-4002-99d3-1478f87fd429">Anal cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal cancer, advanced (off-label use):</b>
<b>IV:</b> 80 mg/m<sup>2</sup> on days 1, 8, and 15 every 4 weeks (in combination with carboplatin) for 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32530769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32530769'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> once every 3 weeks (in combination with carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25012155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25012155'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71e76000-039f-40ca-9de6-4a08c97ec284">Bladder cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>B</b>
<b>ladder </b>
<b>cancer, advanced or metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Paclitaxel/gemcitabine regimens:</i>
<b>IV: </b>150 mg/m<sup>2</sup> every 2 weeks (in combination with gemcitabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11753976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11753976'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> over 1 hour every 3 weeks (in combination with gemcitabine) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11408496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11408496'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> over 3 hours once every 3 weeks (in combination with gemcitabine) for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20682548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20682548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Paclitaxel/cisplatin/gemcitabine (PCG) regimen: </i>
<b>IV: </b>80 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with cisplatin and gemcitabine; refer to protocol for administration sequence details) for up to 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22370319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22370319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent paclitaxel: </i>
<b>IV: </b>80 mg/m<sup>2</sup> over 1 hour once weekly until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11844814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11844814'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chemoradiation (muscle invasive bladder cancer)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: <b>IV: </b>50 mg/m<sup>2</sup> on days 1, 8, and 15 (in combination with cisplatin and radiation), followed by consolidation chemoradiation (in patients who achieved a complete response) of 50 mg/m<sup>2</sup> on days 1 and 8 (in combination with cisplatin and radiation).</p>
<p style="text-indent:-2em;margin-left:6em;">Adjuvant chemotherapy (following chemoradiation and surgery): <b>IV: </b>50 mg/m<sup>2</sup> on days 1 and 8 (in combination with gemcitabine and cisplatin) every 3 weeks for 4 cycles. Refer to protocol for further details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23823157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23823157'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37c6f975-d09e-4942-923c-df308ec4ae33">Breast cancer, adjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant treatment:</b>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AC-T (dose dense)</i>: <b>IV: </b>175 mg/m<sup>2</sup> every 2 weeks for 4 cycles (with growth factor support; following 4 cycles of dose-dense doxorubicin and cyclophosphamide [AC]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12668651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12668651'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AC</i>
<i>-TH (HER-2 positive): </i>
<b>IV: </b>80 mg/m<sup>2</sup> once weekly for 12 weeks <b>or</b> 175 mg/m<sup>2</sup> every 3 weeks for 4 cycles (in combination with trastuzumab, following 4 cycles of AC) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16236738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16236738'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> every 2 weeks for 4 cycles (with growth factor support; in combination with trastuzumab, following 4 cycles of dose-dense AC) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18323546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18323546'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AC-THP (neoadjuvant therapy; HER-2 positive): </i>
<b>IV: </b>80 mg/m<sup>2</sup> once weekly for 12 weeks (in combination with pertuzumab and trastuzumab; following 4 cycles of dose-dense AC) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28057664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28057664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>TH (</i>
<i>HER-2 positive): </i>
<b>IV: </b>80 mg/m<sup>2</sup> once weekly for 12 weeks (in combination with trastuzumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25564897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25564897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Keynote-522 regimen (early triple-negative breast cancer; neoadjuvant therapy): </i>
<b>IV:</b> 80 mg/m<sup>2</sup> once weekly (in combination with carboplatin and pembrolizumab [first neoadjuvant therapy]) for 12 weeks, followed by second neoadjuvant therapy of pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32101663','lexi-content-ref-35139274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32101663','lexi-content-ref-35139274'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46ff64d6-1348-4bbe-b79e-1617c09b78ef">Breast cancer, metastatic or relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic or relapsed: IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations: </i>
<b>IV:</b> 80 mg/m<sup>2</sup> once weekly (in combination with trastuzumab and pertuzumab); if progression-free after 6 months, paclitaxel may be discontinued and trastuzumab and pertuzumab continued until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25547504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25547504'])">Ref</a></span>) <b>or </b>90 mg/m<sup>2</sup> on days 1, 8, and 15 of a 28-day cycle (in combination with bevacizumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18160686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18160686'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with gemcitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18711184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18711184'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c4023e8-d39d-422a-aeed-017ceafae3f7">Cervical cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, advanced (off-label use): IV:</b> 135 or 175 mg/m<sup>2</sup> every 3 weeks (in combination with bevacizumab and cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24552320','lexi-content-ref-28756902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24552320','lexi-content-ref-28756902'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> every 3 weeks (in combination with bevacizumab and topotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24552320','lexi-content-ref-28756902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24552320','lexi-content-ref-28756902'])">Ref</a></span>) <b>or</b> 135 mg/m<sup>2</sup> over 24 hours every 3 weeks (in combination with cisplatin) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19720909','lexi-content-ref-15284262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19720909','lexi-content-ref-15284262'])">Ref</a></span>) <b>or </b>135 mg/m<sup>2</sup> over 3 hours every 3 weeks on day 1 (in combination with carboplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25732161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25732161'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with pembrolizumab and either cisplatin or carboplatin, ± bevacizumab) for 6 cycles; patients could continue chemotherapy beyond 6 cycles if experiencing clinical benefit without unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34534429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34534429'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e78ab22-88ee-4724-83ea-ceee9790b47e">Endometrial cancer, advanced or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial </b>
<b>cancer, advanced or recurrent (off-label use):</b>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours (135 mg/m<sup>2</sup> in patients with a history of pelvic/spine irradiation) on day 1 every 3 weeks (in combination with carboplatin) for up to 7 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33078978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33078978'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin and dostarlimab) for 6 cycles, followed by dostarlimab monotherapy until disease progression, unacceptable toxicity, or for up to 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36972026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36972026'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin) for 6 to 9 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18299146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18299146'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> over 1 hour on days 1, 8, and 15 every 28 days (in combination with carboplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17380438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17380438'])">Ref</a></span>) <b>or</b>
<i>(for HER2-positive uterine serous cancer)</i> 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin and trastuzumab) for ~6 cycles, followed by trastuzumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29584549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29584549'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> over 1 hour on days 1, 8, 15, and 22 every 28 days for at least 2 cycles and until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18307021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18307021'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks for 10 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8922203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8922203'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ef78abe-9934-4dae-aa6d-4c235dbb23a7">Esophageal cancer, metastatic or unresectable locally advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, metastatic or unresectable locally advanced (off-label use): IV:</b> 90 mg/m<sup>2</sup> over 3 hours on day 1 every 14 days (in combination with cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9716036']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9716036'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> (cycle 1; escalated to 225 mg/m<sup>2</sup> in cycle 2 if acceptable ANC and platelets) over 3 hours on day 1 every 3 weeks (in combination with carboplatin) until best response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151955'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> over 1 hour on days 1, 8, 15, and 22 every 28 days (as a single agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17351256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17351256'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4625946c-f1e0-4e05-81c6-dbfa353595ca">Esophageal/esophagogastric cancer, preoperative chemoradiation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal/esophagogastric cancer, preoperative chemoradiation (off-label use):</b>
<b>IV:</b> 50 mg/m<sup>2</sup> over 1 hour on days 1, 8, 15, 22, and 29 (in combination with carboplatin and radiation therapy) followed by surgery within 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22646630','lexi-content-ref-16670722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22646630','lexi-content-ref-16670722'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5cc1b1e4-9894-4d18-b8ab-9121dad649c6">Gastric cancer, metastatic or unresectable locally advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, metastatic or unresectable locally advanced (off-label use): IV:</b> 80 mg/m<sup>2</sup> on days 1, 8, and 15 every 28 days (in combination with ramucirumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25240821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25240821'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> (cycle 1; escalated to 225 mg/m<sup>2</sup> in cycle 2 if acceptable ANC and platelets) over 3 hours on day 1 every 3 weeks (in combination with carboplatin); evaluate for response every 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12576922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12576922'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> on days 1, 8, and 15 every 28 days (as a single agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24190112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24190112'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb13a230-c3e9-4d98-8e1c-329ed6d201bb">Gestational trophoblastic neoplasia, high-risk, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia, high-risk, refractory (off-label use): </b>
<i>TP/TE regimen:</i>
<b>IV: </b>135 mg/m<sup>2</sup> over 3 hours on days 1 and 15 of a 28-day cycle (in combination with cisplatin and etoposide; TP [paclitaxel and cisplatin] alternates every 2 weeks with TE [paclitaxel and etoposide]); continue until hCG level is normal for at least 8 weeks, or until treatment resistance (plateaued or rising hCG) or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18453518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18453518'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a6ffe37-7a9c-420d-ac96-bc4430773ee0">Head and neck cancers, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancers, advanced (off-label use):</b>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 weeks (in combination with cisplatin) for at least 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15908667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15908667'])">Ref</a></span>) <b>or </b>80 mg/m<sup>2</sup> over 1 hour once weekly for 6 consecutive weeks, or until disease progression or unacceptable toxicity (if disease response or stabilization occurred) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19863327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19863327'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="415e018e-821a-43c7-997f-06babe54bbcd">Melanoma, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, advanced or metastatic (alternative therapy) (off-label use):</b>
<b>IV:</b> 225 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin) for 4 cycles followed by (if dose not previously reduced) 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin) for up to 6 additional cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23248256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23248256'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 8, and 15 every 4 weeks (in combination with carboplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16342250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16342250'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c818fdd2-0859-4362-9aae-976c7de99cda">Non–small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer:</b>
<b>IV:</b> 135 mg/m<sup>2</sup> over 24 hours every 3 weeks (in combination with cisplatin) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations</i>: <b>IV:</b> 200 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with carboplatin and cemiplimab) for 4 cycles followed by cemiplimab until disease progression or unacceptable toxicity, or for up to 108 weeks; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36008722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36008722'])">Ref</a></span>) <b>or </b>175 or 200 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with carboplatin and nivolumab; neoadjuvant therapy) for up to 3 cycles; refer to protocol for further information, including histology details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35403841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35403841'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with carboplatin, nivolumab, and ipilimumab; squamous histology) for 2 cycles; nivolumab/ipilimumab therapy continued until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33476593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33476593'])">Ref</a></span>) <b>or </b>200 mg/m<sup>2</sup> on day 1 every 3 weeks for 4 cycles (in combination with pembrolizumab and carboplatin) followed by pembrolizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280635'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> (175 mg/m<sup>2</sup> for Asian patients) on day 1 every 3 weeks for 4 to 6 cycles (in combination with atezolizumab, bevacizumab [non-squamous non-small cell lung cancer], and carboplatin) followed by atezolizumab/bevacizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863955'])">Ref</a></span>) <b>or </b>200 mg/m<sup>2</sup> on day 1 every 3 weeks for 6 cycles (in combination with carboplatin and bevacizumab) followed by bevacizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17167137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17167137'])">Ref</a></span>) <b>or </b>200 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin) for at least 3 cycles and until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17079694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17079694'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ca88c47-fed2-4025-88d5-3331e749f45f">Ovarian cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Previously treated:</i>
<b>IV:</b> 135 or 175 mg/m<sup>2</sup> over 3 hours every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Previously untreated:</i>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 weeks (in combination with cisplatin) or 135 mg/m<sup>2</sup> over 24 hours administered every 3 weeks (in combination with cisplatin).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Previously untreated (off-label route): </i>
<b>Intraperitoneal:</b> 60 mg/m<sup>2</sup> on day 8 of a 21-day treatment cycle for 6 cycles, in combination with IV paclitaxel (135 mg/m<sup>2</sup> over 24 hours on day 1) and intraperitoneal cisplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16394300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16394300'])">Ref</a></span>). <b>Note:</b> Administration of intraperitoneal paclitaxel should include the standard paclitaxel premedication regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Previously untreated (off-label combinations):</i>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 weeks (in combination with carboplatin) for 6 cycles, or 60 mg/m<sup>2</sup> over 1 hour weekly (in combination with carboplatin) for 18 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24582486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24582486'])">Ref</a></span>) <b>or </b>175 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with bevacizumab [delayed until cycle 2] and carboplatin) for up to 6 cycles, followed by bevacizumab monotherapy for a total of up to 22 cycles or until disease progression (whichever occurs earlier) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22204724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22204724'])">Ref</a></span>) <b>or </b>80 mg/m<sup>2</sup> over 1 hour on days 1, 8, and 15 every 3 weeks (in combination with carboplatin) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neoadjuvant therapy (off-label combination/schedule):</i>
<b>Note:</b> According to guidelines from the Society of Gynecologic Oncology and American Society of Clinical Oncology for neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer, neoadjuvant therapy should be utilized only in properly selected patients. Selection criteria include patients with newly diagnosed suspected stage IIIC or IV ovarian cancer who have a high perioperative risk profile and/or a low likelihood of achieving cytoreduction to &lt;1 cm of residual disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27502591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27502591'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin) for 3 neoadjuvant cycles, followed by debulking surgery, followed by 3 additional chemotherapy cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26002111','lexi-content-ref-20818904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26002111','lexi-content-ref-20818904'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with carboplatin) for 3 to 4 neoadjuvant cycles, followed by debulking surgery, followed by 2 to 3 additional chemotherapy cycles, for a total of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26998845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26998845'])">Ref</a></span>) <b>or </b>175 mg/m<sup>2</sup> over 3 hours on day 1 every 3 weeks (in combination with carboplatin) for a total of 6 cycles, with debulking surgery occurring after cycles 3 to 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> over 1 hour on days 1, 8, and 15 every 3 weeks (in combination with carboplatin) for a total of 6 cycles, with debulking surgery occurring after cycles 3 to 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27acb893-188a-4f79-83fe-afa3caf2d225">Penile cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Penile cancer, metastatic (off-label use):</b>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 to 4 weeks (in combination with ifosfamide and cisplatin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20625118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20625118'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6379e00-1d0d-4a31-8fd9-f9acd15e1849">Small cell lung cancer, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, relapsed/refractory (off-label use):</b>
<b>IV:</b> 175 mg/m<sup>2</sup> over 3 hours every 3 weeks (as a single agent) for up to 5 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9461009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9461009'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> over 1 hour weekly for 6 weeks of an 8-week treatment cycle (as a single agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16739353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16739353'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="832dd9fd-9e94-4b46-8632-c026300ffcb1">Soft tissue sarcoma, angiosarcoma, advanced/unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma, angiosarcoma, advanced/unresectable (off-label use): IV:</b> 80 mg/m<sup>2</sup> over 1 hour on days 1, 8, and 15 of a 4-week treatment cycle (as a single agent) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18809609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18809609'])">Ref</a></span>) <b>or</b> 135 to 175 mg/m<sup>2</sup> over 3 hours every 3 weeks (as a single agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18771914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18771914'])">Ref</a></span>) <b>or</b> 75 to 100 mg/m<sup>2</sup> once weekly (as a single agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18771914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18771914'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fceac783-14ca-4c0b-b03d-2c33a364f04d">Testicular germ cell tumors, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular germ cell tumors, relapsed/refractory (off-label use):</b>
<b>IV:</b> 80 mg/m<sup>2</sup> over 1 hour on days 1 and 8 of a 3-week treatment cycle (in combination with gemcitabine and oxaliplatin) for 2 cycles beyond best response and up to a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18006893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18006893'])">Ref</a></span>) <b>or</b> 250 mg/m<sup>2</sup> over 24 hours on day 1 of a 3-week treatment cycle (in combination with ifosfamide, mesna, cisplatin, and filgrastim) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16170162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16170162'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> over 1 hour on days 1, 8, and 15 of a 4-week treatment cycle (in combination with gemcitabine) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17290059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17290059'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1082959-432b-4e5a-8810-eec87b23dc6e">Thymoma/thymic carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymoma/thymic carcinoma, advanced (off-label use):</b>
<b>IV:</b> 225 mg/m<sup>2</sup> over 3 hours every 3 weeks (in combination with carboplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21502559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21502559'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34f18e7a-b0b8-43f7-af13-c9e478e01ef6">Thyroid cancer, anaplastic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, anaplastic (off-label use; based on limited data</b>
<b>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant or radiosensitizing therapy:</i>
<b>IV: </b>30 to 60 mg/m<sup>2</sup> once weekly as a single agent <b>or</b> 50 mg/m<sup>2</sup> once weekly (in combination with carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23130564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23130564'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i>
<b>IV: </b>60 to 90 mg/m<sup>2</sup> once weekly as a single agent <b>or</b> 135 to 200 mg/m<sup>2</sup> once every 3 to 4 weeks as a single agent <b>or</b> 60 to 100 mg/m<sup>2</sup> once weekly (in combination with carboplatin) <b>or</b> 135 to 175 mg/m<sup>2</sup> once every 3 to 4 weeks (in combination with carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23130564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23130564'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abf998a3-72fe-40c4-a3e9-57f7fa6c7507">Unknown primary adenocarcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary adenocarcinoma (off-label use):</b>
<b>IV:</b> 200 mg/m<sup>2</sup> over 3 hours every 3 weeks (in combination with carboplatin) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10963638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10963638'])">Ref</a></span>) <b>or</b> 200 mg/m<sup>2</sup> over 1 hour every 3 weeks (in combination with carboplatin and etoposide) for 4 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11135228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11135228'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991022"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV: </b>No dosage adjustment likely to be necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-30942181','lexi-content-ref-12209686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-30942181','lexi-content-ref-12209686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18476951','lexi-content-ref-16937541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18476951','lexi-content-ref-16937541'])">Ref</a></span>): <b>IV:</b> No dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8780924','lexi-content-ref-18476951','lexi-content-ref-20118214','lexi-content-ref-11240716','lexi-content-ref-16937541','lexi-content-ref-22966334','lexi-content-ref-30942181','lexi-content-ref-11812097','lexi-content-ref-17009648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8780924','lexi-content-ref-18476951','lexi-content-ref-20118214','lexi-content-ref-11240716','lexi-content-ref-16937541','lexi-content-ref-22966334','lexi-content-ref-30942181','lexi-content-ref-11812097','lexi-content-ref-17009648'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18204842','lexi-content-ref-32294609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18204842','lexi-content-ref-32294609'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988236"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The manufacturer's labeled dosage adjustment recommendations are based upon the patient's first course of therapy where the usual dose (in patients with normal hepatic function) would be 135 mg/m<sup>2</sup> dose over 24 hours or the 175 mg/m<sup>2</sup> dose over 3 hours. Dosage in subsequent courses should be based upon individual tolerance. Adjustments for other regimens are not available.</p>
<p style="text-indent:-2em;margin-left:2em;">24-hour infusion:</p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &lt;2 times upper limit of normal (ULN) and bilirubin level ≤1.5 mg/dL: 135 mg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases 2 to &lt;10 times ULN and bilirubin level ≤1.5 mg/dL: 100 mg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &lt;10 times ULN and bilirubin level 1.6 to 7.5 mg/dL: 50 mg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases ≥10 times ULN or bilirubin level &gt;7.5 mg/dL: Avoid use</p>
<p style="text-indent:-2em;margin-left:2em;">3-hour infusion:</p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &lt;10 times ULN and bilirubin level ≤1.25 times ULN: 175 mg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &lt;10 times ULN and bilirubin level 1.26 to 2 times ULN: 135 mg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &lt;10 times ULN and bilirubin level 2.01 to 5 times ULN: 90 mg/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases ≥10 times ULN or bilirubin level &gt;5 times ULN: Avoid use</p></div>
<div class="block doo drugH1Div" id="F20342801"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F205628"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to protocol and/or study reference for specific dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage modification for toxicity (solid tumors, including ovary, breast, and lung carcinoma):</b> Adjustment recommendations are based on the labeled doses (135 mg/m<sup>2</sup> dose over 3 hours or 24 hours every 3 weeks <b>or</b> 175 mg/m<sup>2</sup> dose over 3 hours every 3 weeks): Courses of paclitaxel should not be repeated until the neutrophil count is ≥1,500/mm<sup>3</sup> and the platelet count is ≥100,000/mm<sup>3</sup>; reduce dosage by 20% for patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil &lt;500/mm<sup>3</sup> for a week or longer).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage modification for immunosuppression in AIDS-related Kaposi sarcoma:</b> Adjustment recommendations are based on the labeled doses (135 mg/m<sup>2</sup> over 3 hours every 3 weeks <b>or</b> 100 mg/m<sup>2</sup> over 3 hours every 2 weeks): Paclitaxel should not be given to patients with HIV if the baseline or subsequent neutrophil count is &lt;1,000/mm<sup>3</sup>. Additional modifications include: Reduce dosage of dexamethasone in premedication to 10 mg orally; reduce dosage by 20% in patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil &lt;500/mm<sup>3</sup> for a week or longer); initiate concurrent hematopoietic growth factor (G-CSF) as clinically indicated.</p></div>
<div class="block doe drugH1Div" id="F205587"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F57179085"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia </b>is the main dose-limiting hematologic toxicity of paclitaxel. Severe, grade 4 neutropenia and febrile neutropenia have been reported. Less frequently, paclitaxel may cause <b>thrombocytopenia,</b> and <b>anemia</b> but severe cases are rare. Neutrophil nadir is generally rapidly reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17877447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17877447'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; neutrophil nadir typically occurs at a median of 11 days. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7989941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7989941'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extent of prior cytotoxic chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17877447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17877447'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate, severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, <b>angioedema</b>, and generalized <b>urticaria </b>have occurred with paclitaxel. All grade hypersensitivity reactions occur in ~10% of premedicated patients. Fatal hypersensitivity reactions have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11855881','lexi-content-ref-10623699','lexi-content-ref-28965634','lexi-content-ref-27997900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11855881','lexi-content-ref-10623699','lexi-content-ref-28965634','lexi-content-ref-27997900'])">Ref</a></span>). Delayed hypersensitivity reactions are less common and include <b>maculopapular rash</b>, <b>Stevens-Johnson syndrome/toxic epidermal necrolysis</b> (SJS/TEN), and <b>acute generalized exanthematous pustulosis</b> (AGEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15154637','lexi-content-ref-35379510','lexi-content-ref-24740483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15154637','lexi-content-ref-35379510','lexi-content-ref-24740483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Immediate hypersensitivity reactions: Non–dose-related, not schedule dependent. While patients may have direct immunologic response to paclitaxel itself, the hypersensitivity reactions are more often associated with the solubilizing agent, polyoxyl 35 castor oil (Cremophor EL, Kolliphor EL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28881914','lexi-content-ref-1972736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28881914','lexi-content-ref-1972736'])">Ref</a></span>). These reactions are likely due to complement activation or direct release of mast cell mediators such as histamine and tryptase, although may be IgE or IgG-mediated responses directed against the taxane moiety or Kolliphor EL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17522249','lexi-content-ref-24740483','lexi-content-ref-26725998','lexi-content-ref-28881914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17522249','lexi-content-ref-24740483','lexi-content-ref-26725998','lexi-content-ref-28881914'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Delayed hypersensitivity reactions are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Immediate hypersensitivity reactions: Rapid; often occur within the first 30 minutes of infusion and rarely after the third course of paclitaxel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33068367','lexi-content-ref-1972736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33068367','lexi-content-ref-1972736'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Delayed hypersensitivity reactions: Varied; may occur 48 hours to 1 week after paclitaxel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15154637','lexi-content-ref-35379510','lexi-content-ref-Tavera.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15154637','lexi-content-ref-35379510','lexi-content-ref-Tavera.1'])">Ref</a></span>). Delayed reactions may predispose patients to severe or fatal immediate hypersensitivity reactions with subsequent doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21262103','lexi-content-ref-24740483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21262103','lexi-content-ref-24740483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of hypersensitivity to other drugs formulated in polyoxyl 35 castor oil (Cremophor EL, Kolliphor EL)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hypersensitivity to other formulations of paclitaxel (such as nab-paclitaxel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24740483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24740483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28493032','lexi-content-ref-33068367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28493032','lexi-content-ref-33068367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (BMI &gt;25) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15791461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15791461'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral neuropathy</b>, primarily a distal sensory neuropathy, may occur with paclitaxel. Neuropathy presents as a mixture of paresthesias and dysesthesias, including burning, numbness, tingling, and shooting pains, typically in a stocking-glove distribution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14718800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14718800'])">Ref</a></span>). While severe symptoms are unusual, peripheral neuropathy often leads to subsequent dose reductions in many patients. Most mild to moderate cases resolve several months after discontinuation but may be longer in patients with diabetes. Severe neuropathy may be irreversible in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25870378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25870378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose and cumulative dose-related; Taxanes may either be directly toxic to nerve cells and/or aggregation of microtubules in neuronal cells may lead to neuropathies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14718798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14718798'])">Ref</a></span>). The tips of the longest nerves are affected first, contributing to its distribution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26004917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26004917'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; onset is dose and cumulative dose-dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25870378','lexi-content-ref-16110015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25870378','lexi-content-ref-16110015'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose and cumulative dose</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27325863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27325863'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with diabetes (with or without preexisting neuropathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34085148','lexi-content-ref-27325863','lexi-content-ref-34436039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34085148','lexi-content-ref-27325863','lexi-content-ref-34436039'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent or sequential treatment with other neuropathy inducing chemotherapies (eg, platinums, vinca, proteosome inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25870378','lexi-content-ref-27325863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25870378','lexi-content-ref-27325863'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity and low physical activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27794123']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27794123'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F205548"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG abnormality (14% to 23%), edema (21%; severe edema: 1%), hypotension (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (87%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (38%), nausea and vomiting (52%), stomatitis (17% to 31%; grade 3/4: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (47% to 90%; grades 3/4: 2% to 16%), hemorrhage (14%), leukopenia (90%; grade 4: 17%), neutropenia (78% to 98%; grade 4: 14% to 75%), thrombocytopenia (4% to 20%; grades 3/4: 1% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (22%), increased serum aspartate aminotransferase (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (31% to 45%; severe hypersensitivity reaction: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (15% to 30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (17%), peripheral neuropathy (42% to 70%; grades 3/4: ≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤60%), myalgia (≤60%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (3%), cardiac arrhythmia (≤1%; including bigeminy, complete atrioventricular block, ventricular tachycardia [asymptomatic]), hypertension (≤1%), syncope (≤1%), venous thrombosis (≤1%)</p>
<p style="text-indent:0em;margin-left:2em;">Dermatologic: Changes in nails (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (≤4%), angioedema (≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Ataxia, encephalopathy, tonic-clonic seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Peritonitis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site, skin discoloration at injection site, swelling at injection site, tenderness at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Lodha 2021), atrial fibrillation (Arbuck 1993), pulmonary embolism, supraventricular tachycardia (Arbuck 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Medeiros 2022), maculopapular rash (Picard 2015), pruritus, skin edema (diffuse), skin sclerosis, Stevens-Johnson syndrome (Hiraki 2004), thickening of skin, toxic epidermal necrolysis (Picard 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, esophagitis, intestinal obstruction, intestinal perforation, ischemic colitis, neutropenic enterocolitis, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites, hepatic encephalopathy, hepatic necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Cellulitis at injection site, fibrosis at injection site, induration at injection site, injection-site phlebitis, local skin exfoliation (injection site), tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Autonomic neuropathy, confusion, dizziness, headache, malaise, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Exacerbation of scleroderma, subacute cutaneous lupus erythematosus (Sibaud 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, increased lacrimation, optic nerve damage, photopsia, visual disturbance (including scintillating scotomata and visual floaters)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, pleural effusion, pulmonary fibrosis, respiratory failure</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Radiation recall phenomenon</p></div>
<div class="block coi drugH1Div" id="F205563"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to paclitaxel, polyoxyl 35/polyoxyethylated castor oil (Cremophor EL), or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts &lt;1,500/mm<sup>3</sup>;  treatment of Kaposi sarcoma in patients with baseline neutrophil counts &lt;1,000/mm<sup>3</sup>.</p></div>
<div class="block war drugH1Div" id="F205545"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Infusion-related hypotension, bradycardia, and/or hypertension may occur. Rare but severe conduction abnormalities have been reported. In a scientific statement from the American Heart Association, conventional paclitaxel has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016])</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Paclitaxel is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Injection-site reactions are generally mild (skin discoloration, tenderness, erythema, or swelling) and occur more commonly with an extended infusion duration (eg, 24 hours); injection-site reactions may be delayed (7 to 10 days). More severe reactions (phlebitis, cellulitis, skin exfoliation, necrosis, fibrosis, and induration) have also been reported. Recall skin reactions may occur despite administering through a different IV site.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic dysfunction (myelotoxicity may be worsened in patients with total bilirubin &gt;2 times ULN); dose reductions are recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients due to increased risk of toxicity (severe neutropenia, neuropathy, and cardiovascular events).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Excipients: Conventional paclitaxel formulations contain polyoxyl 35/polyoxyethylated castor oil (Cremophor EL), which is associated with hypersensitivity reactions. Formulations also contain dehydrated alcohol which may cause adverse CNS effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intraperitoneal administration: Intraperitoneal administration of paclitaxel is associated with a higher incidence of chemotherapy- related toxicity (Armstrong 2006).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878575"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">CNS toxicity has been reported in pediatric patients receiving high doses of paclitaxel (350 to 420 mg/m<sup>2</sup> as a 3-hour infusion) possibly due to the ethanol contained in the formulation.</p></div>
<div class="block dosfc drugH1Div" id="F25575978"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Paclitaxel injection contains polyoxyl 35/olyoxyethylated castor oil (Cremophor EL) </p></div>
<div class="block foc drugH1Div" id="F205555"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/16.7 mL (16.7 mL); 30 mg/5 mL (5 mL); 150 mg/25 mL (25 mL); 300 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/16.7 mL (16.7 mL [DSC]); 30 mg/5 mL (5 mL [DSC]); 300 mg/50 mL (50 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F205541"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323590"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (PACLitaxel Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/5 mL (per mL): $1.92 - $5.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/16.7 mL (per mL): $1.22 - $4.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/25 mL (per mL): $3.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/50 mL (per mL): $0.91 - $3.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867811"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/mL (5 mL, 16.7 mL, 25 mL, 50 mL, 100 mL); 30 mg/5 mL (5 mL)</p></div>
<div class="block adm drugH1Div" id="F205560"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 3 or 24 hours (depending on indication/protocol); some off-label protocols use a 1-hour infusion. Infuse through a 0.22-micron in-line filter and polyethylene-lined (non-PVC) administration set. When administered as a part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence recommendation.</p>
<p style="text-indent:-2em;margin-left:4em;">Premedication is recommended to prevent hypersensitivity reactions. Refer to "Dosing: Adult" for premedication regimen details.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Irritant with vesicant-like properties; avoid extravasation. Ensure proper needle or catheter position prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; initiate antidote (hyaluronidase) if appropriate; remove needle/cannula; elevate extremity. Information conflicts regarding the use of warm or cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-Polovich.1'])">Ref</a></span>). Clinical experience suggests hyaluronidase may be used in the management of paclitaxel extravasations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-12690542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-12690542'])">Ref</a></span>); data is limited.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If using hyaluronidase:</i> If needle/cannula still in place: Administer 1 to 6 mL (150 units/mL) into existing IV line; usual dose is 1 mL for each 1 mL of extravasated drug; if needle/cannula has been removed, inject subcutaneously in a clockwise manner around area of extravasation; may repeat several times over the next 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940','lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940','lexi-content-ref-22997449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Intraperitoneal (off-label route): Solution was prepared in warmed saline and infused as rapidly as possible through an implantable intraperitoneal catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16394300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16394300'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132761"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F205559"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b> Adjuvant treatment of node-positive breast cancer (as sequential therapy following anthracycline-containing combination chemotherapy); treatment of metastatic breast cancer after failure of combination chemotherapy (for metastatic disease) or relapse within 6 months of adjuvant chemotherapy (prior therapy should have included an anthracycline unless contraindicated).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kaposi sarcoma (AIDS-related):</b> Second-line treatment of AIDS-related Kaposi sarcoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer:</b> First-line treatment of non-small cell lung cancer (in combination with cisplatin) in patients who are not candidates for potentially curative surgery and/or radiation therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer:</b> Subsequent therapy for treatment of advanced ovarian cancer; first-line therapy of ovarian cancer (in combination with cisplatin).</p></div>
<div class="block off-label drugH1Div" id="F25744718"><span class="drugH1">Use: Off-Label: Adult</span><p>Anal cancer (advanced); Bladder cancer, advanced or metastatic; Cervical cancer, advanced; Endometrial cancer, advanced or recurrent; Esophageal cancer (metastatic or unresectable locally advanced); Esophageal/esophagogastric cancer, preoperative chemoradiation; Gastric cancer (metastatic or unresectable locally advanced); Gestational trophoblastic neoplasia, high-risk, refractory; Head and neck cancers, advanced; Melanoma (advanced or metastatic); Penile cancer, metastatic; Small cell lung cancer, relapsed/refractory; Soft tissue sarcoma (angiosarcoma), advanced/unresectable; Testicular germ cell tumors, relapsed/refractory; Thymoma/thymic carcinoma, advanced; Thyroid cancer (anaplastic); Unknown primary adenocarcinoma</p></div>
<div class="block mst drugH1Div" id="F205636"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PACLitaxel may be confused with cabazitaxel, DOCEtaxel, PARoxetine, Paxil</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PACLitaxel (conventional) may be confused with PACLitaxel  (protein-bound)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taxol may be confused with Abraxane, Paxil, Taxotere</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F205622"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (major), CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F205549"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthracyclines: Taxane Derivatives may enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.  Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of PACLitaxel (Conventional). Management: Use of paclitaxel or other narrow therapeutic index CYP2C8 substrates with atazanavir without concurrent ritonavir is not recommended.  If paclitaxel is used with ritonavir-boosted atazanavir, monitor for increased paclitaxel exposure.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bexarotene (Systemic): PACLitaxel (Conventional) may increase the serum concentration of Bexarotene (Systemic). Bexarotene (Systemic) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of PACLitaxel (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of PACLitaxel (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of PACLitaxel (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of PACLitaxel (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of PACLitaxel (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of PACLitaxel (Conventional).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): PACLitaxel (Conventional) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Administer doxorubicin prior to paclitaxel if these agents are used in combination. Monitor cardiac function if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. Management: Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane before platinum is likely warranted<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: May enhance the adverse/toxic effect of PACLitaxel (Conventional). Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: PACLitaxel (Conventional) may enhance the adverse/toxic effect of Vinorelbine. Specifically hematologic toxicity may be increased. PACLitaxel (Conventional) may enhance the neurotoxic effect of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: PACLitaxel (Conventional) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49309058"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients should be advised to avoid becoming pregnant.</p></div>
<div class="block pri drugH1Div" id="F205566"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Paclitaxel crosses the placenta (Berveiller 2012; Berveiller 2019). In one case, paclitaxel was detected in cord blood 7 days after the last maternal dose. Paclitaxel was not detected in cord blood when delivery occurred 21 days after the last maternal dose in a second case (Berveiller 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of paclitaxel may be altered during pregnancy (Van Calsteren 2010; van Hasselt 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Use of paclitaxel may be appropriate for the treatment of breast cancer and some gynecologic cancers during pregnancy (Amant 2019; Korenaga 2020; Loibl 2015; Shachar 2017). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation. Close monitoring is recommended (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F205567"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Paclitaxel is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information is available from a mother (3 months' postpartum) treated with paclitaxel 30 mg/m<sup>2</sup> (56.1 mg) and carboplatin once weekly for papillary thyroid cancer. Milk samples were obtained 4 to 316 hours after the infusion given at the sixth and final week of therapy. The average paclitaxel milk concentration over the testing interval was 0.78 mg/L. Although maternal serum concentrations were not noted in the report, the relative infant dose (RID) to a breastfeeding infant was calculated to be ~17% of the maternal dose. Paclitaxel continued to be detected in breast milk when sampled at 172 hours after the dose and was below the limit of detection (0.08 mg/L) when sampled at 316 hours after the infusion (Griffin 2012). In a second case report, breast milk was sampled over 15 days following the ninth weekly dose of paclitaxel 80 mg/m<sup>2</sup> for the treatment of breast cancer, first diagnosed during pregnancy. Peak breast milk concentrations (0.1114 mg/L) occurred 2.75 hours after the maternal dose and were below the limit of quantification (&lt;0.0025 mg/L) at 71.25 hours. Authors of this study calculated the RID of paclitaxel 72 hours after the maternal dose to be &lt;1%, based on actual maternal weight (Jackson 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in a breastfeeding infant, breastfeeding is not recommended by the manufacturer. Avoidance of breastfeeding for 6 to 10 days after the last paclitaxel dose, based on the serum half-life, has been suggested (ABM [Johnson 2020]).</p></div>
<div class="block mop drugH1Div" id="F205553"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelet count (frequently), liver and kidney function. Monitor for hypersensitivity reactions, vital signs (frequently during the first hour of infusion), continuous cardiac monitoring (patients with conduction abnormalities). Monitor for signs/symptoms of peripheral neuropathy. Monitor infusion site during infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F205544"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G<sub>2</sub> mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.</p></div>
<div class="block phk drugH1Div" id="F205562"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">V<sub>dss</sub>: 24-hour infusion: 227 to 688 L/m<sup>2</sup>; biphasic with initial rapid distribution to the peripheral compartment; later phase is a slow efflux of paclitaxel from the peripheral compartment; widely distributed into body fluids and tissues; affected by dose and duration of infusion</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 89% to 98% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP2C8 and 3A4; forms metabolites (primarily 6α-hydroxypaclitaxel) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children: 4.6 to 17 hours (varies with dose and infusion duration)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">3-hour infusion: Mean (terminal): ~13 to 20 hours</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">24-hour infusion: Mean (terminal): ~16 to 53 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~71%; ~5% as unchanged drug); urine (~14%) </p></div>
<div class="block phksp drugH1Div" id="F51192032"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma paclitaxel exposure is increased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F205568"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Chemotaxel | Ebetaxel | Paclitaxel actavis | Paclitaxel vitane | Taxol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Asotax | Clitaxel | Dalys | Drifen | Erioxal | Paclinova | Paclitaxel biotechno pharma | Paclitaxel conifarma | Paclitaxel delta farma | Paclitaxel Gp pharm | Paclitaxel ima | Paclitaxel kemex | Paclitaxel microsules | Paclitaxel servycal | Paclitaxel Techsphere | Pacliteva | Paklitaxfil | Panataxel | Taxocris | Taxol | Taycovit</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ebetaxel | Paclitaxel accord | Paclitaxel Arcana | Paclitaxel kabi | Paclitaxel mayrhofer | Paclitaxel Pharmachemie | Taxol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Baxter Paclitaxel | Gn Paclitaxel | Oncotaxel | Paclitaxel actavis | Paclitaxel ebewe | Paclitaxel kabi | Paclitaxel pfizer | Paclitaxin | Plaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Xelpac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel accord | Paclitaxel actavis | Paclitaxel ebewe | Paclitaxel EG | Paclitaxel fresenius kabi | Paclitaxel sandoz | Paclitaxin | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Paclitero</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Genexol | Paclitaxel bulgermed | Paclitaxel kabi | Paclitaxin | Pacliteva | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Akssus | Anzatax | Chemiplac | Oncotaxel | Ontax | Paclimeiz | Paclired | Paclitax | Paclitaxel chemicaltech | Pantium | Parexel | Paxel | Taclipaxol | Tarvexol | Taxol | Tevapacli</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel accord | Paclitaxel actavis | Paclitaxel fresenius | Paclitaxel labatec | Paclitaxel Mepha | Paclitaxel Mylan | Paclitaxel sandoz | Paclitaxel teva | Taxol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Paclitero</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Britaxol | Taxodiol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Taxol | Te su | Zi su</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alzene | Ofoxel | Parexel | Placlitax | Tapaklet | Taxela | Taxocris | Taxol | Tevapacli</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Brevitax | Egilitax | Oncotax | Paclimedac | Pacline | Paclitaxel actavis | Paclitaxel kabi | Paclitaxel lachema | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aritaxel | Axitaxel | Bendatax | Eurotaxel | Eurotaxel c | Neotaxan | Pacli OC | Paclisachs | Paclit | Paclitax | Paclitaxel accord | Paclitaxel actavis | Paclitaxel amneal | Paclitaxel aqvida | Paclitaxel aurobindo | Paclitaxel axios | Paclitaxel Bendalis | Paclitaxel Bhardwaj | Paclitaxel ever pharma | Paclitaxel haemato | Paclitaxel Heumann | Paclitaxel hexal | Paclitaxel kabi | Paclitaxel Omnicare | Paclitaxel Oncocorp | Paclitaxel oncotrade | Paclitaxel Onkovis | Paclitaxel Orca | Paclitaxel PhaRes | Paclitaxel Profusio | Paclitaxel ratiopharm | Paclitaxel resolute oncology | Paclitaxel Ribosepharm | Paclitaxel seacross | Paclitaxel simgen | Paclitaxel stada | Paclitaxel stragen | Paclitaxel Sun | Paclitaxel temmler | Paclitaxel Vipharm | Paclitaxel vitane | Paxene | Ribotax | Taxol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Intaxel | Oplaxel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Parexel | Taxocris | Taxol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel actavis | Paclitaxel fresenius kabi | Paclitaxel hospira | Paclitaxel mayne | Paclitaxel teva | Paxene | Taxol | Yewtaxan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Intaxel | Paclitaxel actavis | Paclitaxel ebewe | Paklitaxfil | Taxol | Unitaxel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel accord | Paclitaxel actavis | Paclitaxel Gp pharm | Paclitaxel kabi | Paclitaxel Normon | Paclitaxel ratiopharm | Paclitaxel stada | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel ebewe</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pacligen | Paclitaxel accord | Paclitaxel actavis | Paclitaxel fresenius kabi | Paclitaxel mayne | Paclitaxel Mylan | Paclitaxin | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel accord | Paclitaxel actavis | Paclitaxel Dakota | Paclitaxel kabi | Paclitaxel ratiopharm | Paclitaxel sandoz | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel medac | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Biotaxel | Ovapac | Paclitaxel/Generics | Paclitaxel/kabi | Paclitaxel/Mayne | Paclitol | Paclixel | Pataxel | Paxene | Paxene paclitaxel | Paxital | Taxol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ebetaxel | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel ebewe | Paclitaxel pliva | Paklitaksel Sandoz | Sindaxel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ebetaxel | Genexol | Intaxel | Magytax | Paclitaxel +pharma | Paclitaxel accord | Paclitaxel ebewe | Paclitaxel kabi | Paclitaxel Merck | Paclitaxel teva | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ebetaxel | Paclimedac | Paxomed | Paxus | Santotaxel | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cantaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Medixel | Taxol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adpaxil | Altaxel | Bevetex | Cansure | Celtax | Clixel | Dutaxel | Glantax p | Gros | Kansure | Maclitaxel | Mitotax | Mytaxel | Nanoxel | Oncotaxel | Paclicad | Paclipar | Paclistar | Paclitec | Paclitrust | Petaxel | Relipac | Repacli | Stritoxol | Taxeleon | Taxol | Tortaxel | Zaxol | Zupaxel</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Paclitaxel accord | Paclitaxel actavis | Paclitaxel crinos | Paclitaxel fki | Paclitaxel sandoz | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Drifen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel hospira | Paclitaxel nk | Taxol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cansure | Celtax | Intaxel | Naprotax | Paclitero | Paxel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Genexol | Genexol PM | Intaxel | Neotacs | Pacxel | Padexol | Sandoz paclitaxel | Tanakcell | Taxol | Taxopam | Unitaxel</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ebetaxel</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ebetaxel | Paclitaxel medac | Panataxel | Pataxel | Taxol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Paclimedac | Paclitaxel accord | Paclitaxel ebewe | Paclitaxel kabi | Paclitaxel pliva | Paclitaxel sanoswiss | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel EG | Taxol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Paclitaxel accord | Paclitaxel act | Paclitaxel kabi | Paclitaxel sanoswiss | Paxene | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acupaxil | Anzatax | Paclitaxel Mylan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aclixel | Acoexcel | Asotax | Bristaxol | Coluxon | Daburex | Ebexel | Ifaxol | Nimaril | Ofoxel | Paclisan | Paxec | Plixandel | Sirapeh | Xeltapira | Zuricxel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Cytax | Formoxol | Intaxel | Mitotax | Taxol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Celtax | Paclitaxel aqvida | Paxus</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel accord | Paclitaxel allgen | Paclitaxel ebewe | Paclitaxel fresenius kabi | Paclitaxin | Taxol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pacligen | Paclitaxel accord | Paclitaxel actavis | Paclitaxel fresenius kabi | Paclitaxel hospira | Paclitaxel mayne | Paclitaxel Pharmachemie | Taxol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Paclitaxel actavis | Paclitaxel ebewe | Taxol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Daburex | Paclitas | Paclitex | Panataxel | Taxocris | Taxol | Taycovit</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Brevixel | Cansure | Clipax | Intaxel | Lexatax | Nanoxel | Napro tax | Pacitel | Paclib | Paclihope | Paclinish | Paclitaxel sandoz | Paclitero | Pactal | Paxus | Paxus pm | Taxol | Vexel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Oncotaxel | Paclitaxel ebewe | Paclitaxel liv pharma | Paclixil | Paklitaxfil | Panataxel | Taxol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel ebewe | Paclitaxel hospira | Paclitaxel kabi | Paclitaxelum Accord | Paclitaxelum Teva | Paxenor | Poltaxel | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Onxol | Taxol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel accord | Paclitaxel aps | Paclitaxel teva | Taxol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Drifen | Onxel | Paclitaxel cipla | Paclitaxel filaxis | Paclitaxel fusa | Paclitaxel intas | Paclitaxel kemex | Paclitaxel lasca | Paclitaxel microsules | Paclitaxel nl pharma | Paclitaxel sandoz | Paclitaxel tuteur | Paclitaxel varifarma | Paclitaxel vmg | Paklitaxfil | Panataxel | Parexel | Taxocris</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Taxol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Onxol | Paclitaxel accord</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Abitaxel | Canataxen | Celixel | Intaxel | Kanataxene | Mitotax | Paclitaxel ebewe | Paclitaxel filaxis | Paclitaxel kelun kazpharm | Paclitaxel Lens | Paclitaxel pliva | Paclitaxel teva | Paclitera | Paxene | Sindaxel | Taxacad | Taxol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ebetaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pacligen | Paclitaxel accord | Paclitaxel actavis | Paclitaxel ebewe | Paclitaxel fresenius kabi | Paclitaxel hospira | Paclitaxel teva | Taxol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ebetaxel | Paclitaxin | Taxol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Paclitaxel ebewe | Paclitaxel sandoz | Paklitaksel Kabi | Paklitaksel Mylan | Paxene | Taxol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Egilitax | Paclimedac | Paclitaxel accord | Paclitaxel hospira | Paclitaxel kabi | Paclitaxel ratiopharm | Paxene | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Intaxel | Mitotax | Paclitaxel ebewe | Paclitaxin | Paclitero | Paxoll | Sindaxel | Taxol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Cytopaxel | Drifen | Ebetaxel | Paclitaxel stragen | Sindaxel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anzatax | Ataxil | Ebetaxel | Sindaxel | Taksen | Vitax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anzatax Paclitaxel | Formoxol | Genaxol | Genetaxyl | Intaxel | Phyxol | Taxol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abitaxel | Intaxel | Paclinor | Paclitax | Paclitaxel accord | Paclitaxel actavis | Paclitaxel amaxa | Paclitaxel mb | Paclitero | Stritoxol | Taxomeda</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Napro tax</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dalys | Paclitaxel Glenmark | Paklitaxfil | Taxocris</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clitaxel | Intaxel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord paclitaxel | Anzatax | Aspen Paclitaxel | Cipla Paclitaxel | Ebetaxel | Indaxol | Loxat | Mylan Paclitaxel | Paxitas | Pch paclitaxel | Sandoz paclitaxel | Taxol | Teva-paclitaxel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10958311">
<a name="10958311"></a>Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. <i>Thyroid</i>. 2000;10(7):587-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/10958311/pubmed" id="10958311" target="_blank">10958311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18711184">
<a name="18711184"></a>Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. <i>J Clin Oncol</i>. 2008;26(24):3950-3957. doi:10.1200/JCO.2007.11.9362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18711184/pubmed" id="18711184" target="_blank">18711184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20682548">
<a name="20682548"></a>Albers P, Park SI, Niegisch G, et al; AUO Bladder Cancer Group. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment. <i>Ann Oncol</i>. 2011;22(2):288-294. doi:10.1093/annonc/mdq398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/20682548/pubmed" id="20682548" target="_blank">20682548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21262103">
<a name="21262103"></a>Allergy Asthma Proceedings. A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. <i>Allergy Asthma Proc</i>. 2011;32(1):79. doi:10.2500/aap.2011.32.3409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/21262103/pubmed" id="21262103" target="_blank">21262103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31435648">
<a name="31435648"></a>Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. <i>Ann Oncol</i>. 2019;30(10):1601-1612. doi:10.1093/annonc/mdz228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/31435648/pubmed" id="31435648" target="_blank">31435648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28493032">
<a name="28493032"></a>Aoyama T, Takano M, Miyamoto M, et al. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? <i>Cancer Chemother Pharmacol</i>. 2017;80(1):65-69. doi:10.1007/s00280-017-3332-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28493032/pubmed" id="28493032" target="_blank">28493032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7912518">
<a name="7912518"></a>Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. <i>J Natl Cancer Inst Monogr</i>. 1993;(15):117-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/7912518/pubmed" id="7912518" target="_blank">7912518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16394300">
<a name="16394300"></a>Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. <i>N Engl J Med</i>. 2006;354(1):34-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16394300/pubmed" id="16394300" target="_blank">16394300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007, p 101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8780924">
<a name="8780924"></a>Balat O, Kudelka AP, Edwards CL, Verschraegen C, Mante R, Kavanagh JJ. A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis.<i> Eur J Gynaecol Oncol</i>. 1996;17(3):232-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/8780924/pubmed" id="8780924" target="_blank">8780924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34472667">
<a name="34472667"></a>Barroso-Sousa R, Vaz-Luis I, Di Meglio A, et al. Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer. <i>Oncologist</i>. 2021;26(11):927-933. doi:10.1002/onco.13960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/34472667/pubmed" id="34472667" target="_blank">34472667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18476951">
<a name="18476951"></a>Baur M, Fazeny-Doerner B, Olsen SJ, Dittrich C. High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. <i>Int J Gynecol Cancer</i>. 2008;18(3):564-570. doi:10.1111/j.1525-1438.2007.01048.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18476951/pubmed" id="18476951" target="_blank">18476951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22370319">
<a name="22370319"></a>Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. <i>J Clin Oncol</i>. 2012;30(10):1107-1113. doi:10.1200/JCO.2011.38.6979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/22370319/pubmed" id="22370319" target="_blank">22370319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25519756">
<a name="25519756"></a>Berger MJ, Vargo C, Vincent M, et al. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. <i>Support Care Cancer</i>. 2015;23(7):2019-2024. doi:10.1007/s00520-014-2556-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25519756/pubmed" id="25519756" target="_blank">25519756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30367323">
<a name="30367323"></a>Berveiller P, Mir O, Degrelle SA, et al. Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters. <i>Invest New Drugs</i>. 2019;37(5):1075-1085. doi:10.1007/s10637-018-0677-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/30367323/pubmed" id="30367323" target="_blank">30367323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23174392">
<a name="23174392"></a>Berveiller P, Vinot C, Mir O, et al. Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. <i>Am J Obstet Gynecol</i>. 2012;207(6):514.e1-514.e7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/23174392/pubmed" id="23174392" target="_blank">23174392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18006893">
<a name="18006893"></a>Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. <i>Ann Oncol</i>. 2008;19(3):448-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18006893/pubmed" id="18006893" target="_blank">18006893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9261533">
<a name="9261533"></a>Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. <i>Ann Oncol</i>. 1997;8(6):611-614. doi:10.1023/a:1008207025430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/9261533/pubmed" id="9261533" target="_blank">9261533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10963638">
<a name="10963638"></a>Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. <i>J Clin Oncol</i>. 2000;18(17):3101-3107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/10963638/pubmed" id="10963638" target="_blank">10963638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22204724">
<a name="22204724"></a>Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. <i>N Engl J Med</i>. 2011;365(26):2473-2483. doi:10.1056/NEJMoa1104390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/22204724/pubmed" id="22204724" target="_blank">22204724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35245079">
<a name="35245079"></a>Chuang LT, Temin S, Berek JS; Management and Care of Patients with Invasive Cervical Cancer Resource-Stratified Guideline Expert Panel. Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update. <i>JCO Glob Oncol</i>. 2022;8:e2200027. doi:10.1200/GO.22.00027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/35245079/pubmed" id="35245079" target="_blank">35245079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28717717">
<a name="28717717"></a>Chuang LT, Temin S, Camacho R, et al. Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. <i>J Glob Oncol</i>. 2016;2(5):311-340. doi:10.1200/JGO.2016.003954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28717717/pubmed" id="28717717" target="_blank">28717717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668651">
<a name="12668651"></a>Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <i>J Clin Oncol</i>. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/12668651/pubmed" id="12668651" target="_blank">12668651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31791688">
<a name="31791688"></a>Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. <i>Lancet</i>. 2019;394(10214):2084-2095. doi:10.1016/S0140-6736(19)32259-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/31791688/pubmed" id="31791688" target="_blank">31791688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34534429">
<a name="34534429"></a>Colombo N, Dubot C, Lorusso D, et al; KEYNOTE-826 Investigators. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. <i>N Engl J Med.</i> Published online September 18, 2021. doi:10.1056/NEJMoa2112435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/34534429/pubmed" id="34534429" target="_blank">34534429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18323546">
<a name="18323546"></a>Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. <i>J Clin Oncol</i>. 2008;26(8):1216-1222. doi:10.1200/JCO.2007.12.0733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18323546/pubmed" id="18323546" target="_blank">18323546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25547504">
<a name="25547504"></a>Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>J Clin Oncol</i>. 2015;33(5):442-447. doi:10.1200/JCO.2014.57.1745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25547504/pubmed" id="25547504" target="_blank">25547504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26004917">
<a name="26004917"></a>De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. <i>Crit Rev Oncol Hematol</i>. 2015;96(1):34-45. doi:10.1016/j.critrevonc.2015.04.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/26004917/pubmed" id="26004917" target="_blank">26004917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25870378">
<a name="25870378"></a>de la Morena Barrio P, Conesa MÁ, González-Billalabeitia E, et al. Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. <i>J Natl Compr Canc Netw</i>. 2015;13(4):417-423. doi:10.6004/jnccn.2015.0057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25870378/pubmed" id="25870378" target="_blank">25870378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17290059">
<a name="17290059"></a>Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. <i>J Clin Oncol</i>. 2007;25(5):513-516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17290059/pubmed" id="17290059" target="_blank">17290059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7989941">
<a name="7989941"></a>Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. <i>J Clin Oncol</i>. 1994;12(12):2654-2666. doi:10.1200/JCO.1994.12.12.2654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/7989941/pubmed" id="7989941" target="_blank">7989941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151955">
<a name="15151955"></a>El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. <i>Ann Oncol</i>. 2004;15(6):960-965. doi:10.1093/annonc/mdh230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15151955/pubmed" id="15151955" target="_blank">15151955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151940">
<a name="15151940"></a>Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. <i>Ann Oncol</i>. 2004;15(6):858-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15151940/pubmed" id="15151940" target="_blank">15151940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29584549">
<a name="29584549"></a>Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. <i>J Clin Oncol</i>. 2018;36(20):2044-2051. doi:10.1200/JCO.2017.76.5966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/29584549/pubmed" id="29584549" target="_blank">29584549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26998845">
<a name="26998845"></a>Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. <i>Eur J Cancer</i>. 2016;59:22-33. doi:10.1016/j.ejca.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/26998845/pubmed" id="26998845" target="_blank">26998845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23248256">
<a name="23248256"></a>Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. <i>J Clin Oncol</i>. 2013;31(3):373-379. doi:10.1200/JCO.2012.42.1529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/23248256/pubmed" id="23248256" target="_blank">23248256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of Cancer Therapy. <i>J Clin Oncol</i>. 2005;23(30):7685-7696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35403841">
<a name="35403841"></a>Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. <i>N Engl J Med</i>. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/35403841/pubmed" id="35403841" target="_blank">35403841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12576922">
<a name="12576922"></a>Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. <i>Am J Clin Oncol</i>. 2003;26(1):37-41. doi:10.1097/00000421-200302000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/12576922/pubmed" id="12576922" target="_blank">12576922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908667">
<a name="15908667"></a>Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. <i>J Clin Oncol</i>. 2005;23(15):3562-3567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15908667/pubmed" id="15908667" target="_blank">15908667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36008722">
<a name="36008722"></a>Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. <i>Nat Med.</i> 2022;28(11):2374-2380. doi:10.1038/s41591-022-01977-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/36008722/pubmed" id="36008722" target="_blank">36008722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19863327">
<a name="19863327"></a>Grau JJ, Caballero M, Verger E, Monzó M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. <i>Acta Otolaryngol</i>. 2009;129(11):1294-1299. doi:10.3109/00016480802590451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/19863327/pubmed" id="19863327" target="_blank">19863327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11135228">
<a name="11135228"></a>Greco FA, Burris HA 3rd, Erland JB, et al. Carcinoma of unknown primary site. <i>Cancer</i>. 2000;89(12):2655-2660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11135228/pubmed" id="11135228" target="_blank">11135228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27794123">
<a name="27794123"></a>Greenlee H, Hershman DL, Shi Z, et al. BMI, Lifestyle factors and taxane-induced neuropathy in breast cancer patients: The Pathways Study. <i>J Natl Cancer Inst</i>. 2016;109(2):djw206. doi:10.1093/jnci/djw206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/27794123/pubmed" id="27794123" target="_blank">27794123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23087196">
<a name="23087196"></a>Griffin SJ, Milla M, Baker TE, et al. Transfer of carboplatin and paclitaxel into breast milk. <i>J Hum Lact</i>. 2012;28(4):457-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/23087196/pubmed" id="23087196" target="_blank">23087196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34085148">
<a name="34085148"></a>Gu J, Lu H, Chen C, et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. <i>Support Care Cancer</i>. 2021;29(12):7461-7469. doi:10.1007/s00520-021-06321-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/34085148/pubmed" id="34085148" target="_blank">34085148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14718798">
<a name="14718798"></a>Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. <i>Breast Cancer</i>. 2004;11(1):82-85. doi:10.1007/BF02968008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/14718798/pubmed" id="14718798" target="_blank">14718798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20148860">
<a name="20148860"></a>Hanioka N, Matsumoto K, Saito Y, et al. Functional Characterization of CYP2C8.13 and CYP2C8.14: Catalytic Activities Toward Paclitaxel. <i>Basic Clin Pharmacol Toxicol</i>. 2010;107(1):565-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/20148860/pubmed" id="20148860" target="_blank">20148860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18204842">
<a name="18204842"></a>Heijns JB, van der Burg ME, van Gelder T, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. <i>Cancer Chemother Pharmacol</i>. 2008;62(5):841-847. doi:10.1007/s00280-007-0671-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18204842/pubmed" id="18204842" target="_blank">18204842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27325863">
<a name="27325863"></a>Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. <i>J Clin Oncol</i>. 2016;34(25):3014-3022. doi:10.1200/JCO.2015.66.2346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/27325863/pubmed" id="27325863" target="_blank">27325863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15154637">
<a name="15154637"></a>Hiraki A, Aoe K, Murakami T, Maeda T, Eda R, Takeyama H. Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. <i>Anticancer Res</i>. 2004;24(2C):1135-1137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15154637/pubmed" id="15154637" target="_blank">15154637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24190112">
<a name="24190112"></a>Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. <i>J Clin Oncol</i>. 2013;31(35):4438-4444. doi:10.1200/JCO.2012.48.5805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/24190112/pubmed" id="24190112" target="_blank">24190112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18307021">
<a name="18307021"></a>Homesley HD, Meltzer NP, Nieves L, Vaccarello L, Lowendowski GS, Elbendary AA. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. <i>Int J Clin Oncol</i>. 2008;13(1):62-65. doi:10.1007/s10147-007-0731-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18307021/pubmed" id="18307021" target="_blank">18307021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17351256">
<a name="17351256"></a>Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. <i>Ann Oncol</i>. 2007;18(5):898-902. doi:10.1093/annonc/mdm004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17351256/pubmed" id="17351256" target="_blank">17351256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31363168">
<a name="31363168"></a>Jackson CGCA, Morris T, Hung N, Hung T. Breast milk paclitaxel excretion following intravenous chemotherapy-a case report. <i>Br J Cancer</i>. 2019;121(5):421-424. doi:10.1038/s41416-019-0529-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/31363168/pubmed" id="31363168" target="_blank">31363168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>, 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11240716">
<a name="11240716"></a>Jeyabalan N, Hirte HW, Moens F. Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. <i>Int J Gynecol Cancer</i>. 2000;10(6):463-468. doi:10.1046/j.1525-1438.2000.00072.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11240716/pubmed" id="11240716" target="_blank">11240716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32516007">
<a name="32516007"></a>Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM clinical protocol #34: breast cancer and breastfeeding. <i>Breastfeed Med</i>. 2020;15(7):429-434. doi:10.1089/bfm.2020.29157.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/32516007/pubmed" id="32516007" target="_blank">32516007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16110015">
<a name="16110015"></a>Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. <i>J Clin Oncol</i>. 2005;23(24):5542-5551. doi:10.1200/JCO.2005.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16110015/pubmed" id="16110015" target="_blank">16110015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16937541">
<a name="16937541"></a>Kawate S, Takeyoshi I, Morishita Y. Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer: a case report. <i>World J Gastroenterol</i>. 2006;12(32):5237-5239. doi:10.3748/wjg.v12.i32.5237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16937541/pubmed" id="16937541" target="_blank">16937541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26002111">
<a name="26002111"></a>Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet</i>. 2015;386(9990):249-257. doi:10.1016/S0140-6736(14)62223-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/26002111/pubmed" id="26002111" target="_blank">26002111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25012155">
<a name="25012155"></a>Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. <i>Oncology</i>. 2014;87(2):125-132. doi:10.1159/000361051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25012155/pubmed" id="25012155" target="_blank">25012155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25732161">
<a name="25732161"></a>Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. <i>J Clin Oncol</i>. 2015;33(19):2129-2135. doi:10.1200/JCO.2014.58.4391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25732161/pubmed" id="25732161" target="_blank">25732161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22966334">
<a name="22966334"></a>Kodama J, Sasaki A, Masahiro S, et al. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis.<i> Oncol Lett</i>. 2010;1(3):511-513. doi:10.3892/ol_00000090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/22966334/pubmed" id="22966334" target="_blank">22966334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16170162">
<a name="16170162"></a>Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. <i>J Clin Oncol</i>. 2005;23(27):6549-6555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16170162/pubmed" id="16170162" target="_blank">16170162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32268951">
<a name="32268951"></a>Korenaga TK, Tewari KS. Gynecologic cancer in pregnancy. <i>Gynecol Oncol</i>. 2020;157(3):799-809. doi:10.1016/j.ygyno.2020.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/32268951/pubmed" id="32268951" target="_blank">32268951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14718800">
<a name="14718800"></a>Kuroi K, Shimozuma K. Neurotoxicity of taxanes: symptoms and quality of life assessment. <i>Breast Cancer</i>. 2004;11(1):92-99. doi:10.1007/BF02968010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/14718800/pubmed" id="14718800" target="_blank">14718800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11855881">
<a name="11855881"></a>Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. <i>Gynecol Oncol</i>. 2002;84(3):420-425. doi:10.1006/gyno.2001.6546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11855881/pubmed" id="11855881" target="_blank">11855881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32294609">
<a name="32294609"></a>Labaki C, Rawadi E, Chebel R, Bakouny Z, Droz JP, Kattan JG. Anti-neoplastic agents for patients on peritoneal dialysis: a systematic review. <i>Crit Rev Oncol Hematol.</i> 2020;150:102947. doi:10.1016/j.critrevonc.2020.102947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/32294609/pubmed" id="32294609" target="_blank">32294609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34357780">
<a name="34357780"></a>Lansinger OM, Biedermann S, He Z, Colevas AD. Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. <i>J Clin Oncol</i>. 2021;39(32):3583-3590. doi:10.1200/JCO.21.01200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/34357780/pubmed" id="34357780" target="_blank">34357780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502559">
<a name="21502559"></a>Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. <i>J Clin Oncol</i>. 2011;29(15):2060-2065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/21502559/pubmed" id="21502559" target="_blank">21502559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17522249">
<a name="17522249"></a>Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. <i>Oncologist</i>. 2007;12(5):601-609. doi:10.1634/theoncologist.12-5-601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17522249/pubmed" id="17522249" target="_blank">17522249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8922203">
<a name="8922203"></a>Lissoni A, Zanetta G, Losa G, et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. <i>Ann Oncol</i>. 1996;7(8):861-863. doi:10.1093/oxfordjournals.annonc.a010768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/8922203/pubmed" id="8922203" target="_blank">8922203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-lodha.1">
<a name="lodha.1"></a>Lodha D, Gill R, Vaswani V, et al. Acute Coronary Syndrome - NSTEMI following paclitaxel administration in patient with oral squamous cell carcinoma: case report and review. <i>IOSR Journal of Dental and Medical Sciences.</i>2021;20(1):20-23. doi:10.9790/0853-2004012023</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247818">
<a name="26247818"></a>Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. <i>JAMA Oncol</i>. 2015;1(8):1145-1153. doi:10.1001/jamaoncol.2015.2413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/26247818/pubmed" id="26247818" target="_blank">26247818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623699">
<a name="10623699"></a>Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. <i>J Clin Oncol</i>. 2000;18(1):102-105. doi:10.1200/JCO.2000.18.1.102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/10623699/pubmed" id="10623699" target="_blank">10623699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17877447">
<a name="17877447"></a>Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. <i>Expert Opin Drug Saf</i>. 2007;6(5):609-621. doi:10.1517/14740338.6.5.609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17877447/pubmed" id="17877447" target="_blank">17877447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2015;33(30):3488-3515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35379510">
<a name="35379510"></a>Medeiros ACTR, Corrêa JL, Schultz Junior A, Sarmenghi KDA. Acute localized exanthematous pustulosis induced by paclitaxel. <i>An Bras Dermatol</i>. 2022;97(3):397-398. doi:10.1016/j.abd.2021.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/35379510/pubmed" id="35379510" target="_blank">35379510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11408496">
<a name="11408496"></a>Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. <i>J Clin Oncol</i>. 2001;19(12):3018-3024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11408496/pubmed" id="11408496" target="_blank">11408496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9600818">
<a name="9600818"></a>Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single-dose dexamethasone paclitaxel premedication. <i>Gynecol Oncol</i>. 1998;69(2):122-124. doi:10.1006/gyno.1998.4993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/9600818/pubmed" id="9600818" target="_blank">9600818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33078978">
<a name="33078978"></a>Miller D, Filiaci V, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). <i>J Clin Oncol</i>. 2020;38(33):3841-3850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/33078978/pubmed" id="33078978" target="_blank">33078978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18160686">
<a name="18160686"></a>Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. <i>N Engl J Med</i>. 2007;357(26):2666-2676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18160686/pubmed" id="18160686" target="_blank">18160686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36972026">
<a name="36972026"></a>Mirza MR, Chase DM, Slomovitz BM, et al; RUBY Investigators. Dostarlimab for primary advanced or recurrent endometrial cancer. <i>N Engl J Med</i>. 2023;388(23):2145-2158. doi:10.1056/NEJMoa2216334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/36972026/pubmed" id="36972026" target="_blank">36972026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23823157">
<a name="23823157"></a>Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. <i>Lancet Oncol</i>. 2013;14(9):863-872. doi:10.1016/S1470-2045(13)70255-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/23823157/pubmed" id="23823157" target="_blank">23823157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720909">
<a name="19720909"></a>Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. <i>J Clin Oncol</i>. 2009;27(28):4649-4655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/19720909/pubmed" id="19720909" target="_blank">19720909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15284262">
<a name="15284262"></a>Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. <i>J Clin Oncol</i>. 2004;22(15):3113-3139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15284262/pubmed" id="15284262" target="_blank">15284262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079694">
<a name="17079694"></a>Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. <i>Ann Oncol</i>. 2007;18(2):317-323. doi:10.1093/annonc/mdl377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17079694/pubmed" id="17079694" target="_blank">17079694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novadoz.1">
<a name="Novadoz.1"></a>Paclitaxel [prescribing information]. Piscataway, NJ: Novadoz Pharmaceuticals LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sagent.1">
<a name="Sagent.1"></a>Paclitaxel [prescribing information]. Schaumburg, IL: Sagent; June 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625118">
<a name="20625118"></a>Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. <i>J Clin Oncol</i>. 2010;28(24):3851-3857.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/20625118/pubmed" id="20625118" target="_blank">20625118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29435713">
<a name="29435713"></a>Parinyanitikul N, Tanpipattanakul W, Poovorawan N, et al. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. <i>Support Care Cancer</i>. 2018;26(7):2471-2477. doi:10.1007/s00520-018-4087-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/29435713/pubmed" id="29435713" target="_blank">29435713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33476593">
<a name="33476593"></a>Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/33476593/pubmed" id="33476593" target="_blank">33476593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280635">
<a name="30280635"></a>Paz-Ares L, Luft A, Vicente D, et al; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. <i>N Engl J Med</i>. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/30280635/pubmed" id="30280635" target="_blank">30280635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;(24)(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18299146">
<a name="18299146"></a>Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. <i>Gynecol Oncol</i>. 2008;109(2):250-254. doi:10.1016/j.ygyno.2008.01.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18299146/pubmed" id="18299146" target="_blank">18299146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18809609">
<a name="18809609"></a>Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. <i>J Clin Oncol</i>. 2008;26(32):5269-5274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18809609/pubmed" id="18809609" target="_blank">18809609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9716036">
<a name="9716036"></a>Petrasch S, Welt A, Reinacher A, Graeven U, König M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. <i>Br J Cancer</i>. 1998;78(4):511-514. doi:10.1038/bjc.1998.524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/9716036/pubmed" id="9716036" target="_blank">9716036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24740483">
<a name="24740483"></a>Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. <i>Clin Rev Allergy Immunol</i>. 2015;49(2):177-191. doi:10.1007/s12016-014-8416-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/24740483/pubmed" id="24740483" target="_blank">24740483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28965634">
<a name="28965634"></a>Picard M. Management of hypersensitivity reactions to taxanes. <i>Immunol Allergy Clin North Am</i>. 2017;37(4):679-693. doi:10.1016/j.iac.2017.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28965634/pubmed" id="28965634" target="_blank">28965634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26725998">
<a name="26725998"></a>Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. <i>J Allergy Clin Immunol</i>. 2016;137(4):1154-1164.e12. doi:10.1016/j.jaci.2015.10.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/26725998/pubmed" id="26725998" target="_blank">26725998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24582486">
<a name="24582486"></a>Pignata S, Scambia G, Katsaros D, et al ; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2014;15(4):396-405. doi:10.1016/S1470-2045(14)70049-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/24582486/pubmed" id="24582486" target="_blank">24582486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.1">
<a name="Polovich.1"></a>Polovich M, Whitford JN, Olsen M. <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>. 3rd ed. Oncology Nursing Society; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16342250">
<a name="16342250"></a>Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. <i>Cancer</i>. 2006;106(2):375-382. doi:10.1002/cncr.21611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16342250/pubmed" id="16342250" target="_blank">16342250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32530769">
<a name="32530769"></a>Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. <i>J Clin Oncol</i>. 2020;38(22):2510-2518. doi:10.1200/JCO.19.03266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/32530769/pubmed" id="32530769" target="_blank">32530769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27997900">
<a name="27997900"></a>Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, et al. A difference in the incidences of hypersensitivity reactions to original and generic taxanes. <i>Chemotherapy</i>. 2017;62(2):134-139. doi:10.1159/000450748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/27997900/pubmed" id="27997900" target="_blank">27997900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16236738">
<a name="16236738"></a>Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <i>N Engl J Med</i>. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16236738/pubmed" id="16236738" target="_blank">16236738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28881914">
<a name="28881914"></a>Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2017;28(suppl 4):iv100-iv118. doi:10.1093/annonc/mdx216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28881914/pubmed" id="28881914" target="_blank">28881914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17167137">
<a name="17167137"></a>Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. <i>N Engl J Med</i>. 2006;355(24):2542-2550. doi:10.1056/NEJMoa061884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17167137/pubmed" id="17167137" target="_blank">17167137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15023436">
<a name="15023436"></a>Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. <i>Cancer Treat Rev</i>. 2004;30(2):181-191. doi:10.1016/j.ctrv.2003.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15023436/pubmed" id="15023436" target="_blank">15023436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18771914">
<a name="18771914"></a>Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. <i>Eur J Cancer</i>. 2008;44(16):2433-2436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18771914/pubmed" id="18771914" target="_blank">18771914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35139274">
<a name="35139274"></a>Schmid P, Cortes J, Dent R, et al; KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer.<i> N Engl J</i>
<i>Med</i>. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/35139274/pubmed" id="35139274" target="_blank">35139274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32101663">
<a name="32101663"></a>Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. <i>N Engl J Med</i>. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/32101663/pubmed" id="32101663" target="_blank">32101663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17380438">
<a name="17380438"></a>Secord AA, Havrilesky LJ, Carney ME, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. <i>Int J Clin Oncol</i>. 2007;12(1):31-36. doi:10.1007/s10147-006-0619-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17380438/pubmed" id="17380438" target="_blank">17380438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34436039">
<a name="34436039"></a>Sempere-Bigorra M, Julián-Rochina I, Cauli O. Chemotherapy-induced neuropathy and diabetes: a scoping review. <i>Curr Oncol</i>. 2021;28(4):3124-3138. doi:10.3390/curroncol28040273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/34436039/pubmed" id="34436039" target="_blank">34436039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15791461">
<a name="15791461"></a>Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. <i>Cancer Chemother Pharmacol</i>. 2005;56(1):91-96. doi:10.1007/s00280-004-0924-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/15791461/pubmed" id="15791461" target="_blank">15791461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28232597">
<a name="28232597"></a>Shachar SS, Gallagher K, McGuire K, et al. Multidisciplinary management of breast cancer during pregnancy. <i>Oncologist</i>. 2017;22(3):324-334. doi:10.1634/theoncologist.2016-0208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28232597/pubmed" id="28232597" target="_blank">28232597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27550571">
<a name="27550571"></a>Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. <i>Eur J Dermatol</i>. 2016;26(5):427-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/27550571/pubmed" id="27550571" target="_blank">27550571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23130564">
<a name="23130564"></a>Smallridge RC, Ain KB, Asa SL, et al; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid</i>. 2012;22(11):1104-1139. doi:10.1089/thy.2012.0302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/23130564/pubmed" id="23130564" target="_blank">23130564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9461009">
<a name="9461009"></a>Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. <i>Br J Cancer</i>. 1998;77(2):347-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/9461009/pubmed" id="9461009" target="_blank">9461009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863955">
<a name="29863955"></a>Socinski MA, Jotte RM, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. <i>N Engl J Med</i>. 2018;378(24):2288-2301. doi:10.1056/NEJMoa1716948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/29863955/pubmed" id="29863955" target="_blank">29863955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12690542">
<a name="12690542"></a>Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. <i>Support Care Cancer</i>. 2003;11(5):270-277. doi:10.1007/s00520-003-0441-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/12690542/pubmed" id="12690542" target="_blank">12690542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753976">
<a name="11753976"></a>Sternberg CN, Calabrò F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. <i>Cancer</i>. 2001;92(12):2993-2998.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11753976/pubmed" id="11753976" target="_blank">11753976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28057664">
<a name="28057664"></a>Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. <i>Ann Oncol</i>. 2017;28(4):761-768. doi:10.1093/annonc/mdw695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28057664/pubmed" id="28057664" target="_blank">28057664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tavera.1">
<a name="Tavera.1"></a>Tavera MAU, Angel D, Madrigal-Burgaleta R, Berges P, Alvarez-Cuesta E, Arango RP. Delayed reaction to paclitaxel [abstract 581]. <i>J Allergy Clin Immunol.</i> 2013:AB164.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bristol.1">
<a name="Bristol.1"></a>Taxol (paclitaxel) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24552320">
<a name="24552320"></a>Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. <i>N Engl J Med</i>. 2014;370(8):734-743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/24552320/pubmed" id="24552320" target="_blank">24552320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28756902">
<a name="28756902"></a>Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). <i>Lancet</i>. 2017;390(10103):1654-1663. doi:10.1016/S0140-6736(17)31607-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/28756902/pubmed" id="28756902" target="_blank">28756902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33068367">
<a name="33068367"></a>Thangwonglers T, Santimaleeworagun W, Therasakvichya S, Saengsukkasemsak N, Pimsi P. Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients. <i>Asian Pac J Allergy Immunol</i>. 2020;10.12932/AP-050520-0831. doi:10.12932/AP-050520-0831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/33068367/pubmed" id="33068367" target="_blank">33068367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12844327">
<a name="12844327"></a>ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. <i>Clin Pharmacokinet</i>. 2003;42(7):665-685.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/12844327/pubmed" id="12844327" target="_blank">12844327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25564897">
<a name="25564897"></a>Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. <i>N Engl J Med</i>. 2015;372(2):134-141. doi:10.1056/NEJMoa1406281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25564897/pubmed" id="25564897" target="_blank">25564897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin</i>
<i>Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25009715">
<a name="25009715"></a>Van Calsteren K. Chemotherapy during pregnancy: pharmacokinetics and impact on foetal neurological development. <i>Facts Views Vis Obgyn</i>. 2010;2(4):278-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25009715/pubmed" id="25009715" target="_blank">25009715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22646630">
<a name="22646630"></a>van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. <i>N Engl J Med</i>. 2012;366(22):2074-2084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/22646630/pubmed" id="22646630" target="_blank">22646630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713311">
<a name="24713311"></a>van Hasselt JGC, Van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. <i>Ann Oncol</i>. 2014;25(10)2059-2065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/24713311/pubmed" id="24713311" target="_blank">24713311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16670722">
<a name="16670722"></a>van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study.<i> Br J Cancer</i>. 2006;94(10):1389-1394. doi:10.1038/sj.bjc.6603134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16670722/pubmed" id="16670722" target="_blank">16670722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11844814">
<a name="11844814"></a>Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. <i>J Clin Oncol</i>. 2002;20(4):937-940. doi:10.1200/JCO.2002.20.4.937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11844814/pubmed" id="11844814" target="_blank">11844814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12209686">
<a name="12209686"></a>Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. <i>Cancer</i>. 2002a;95(5):1022-1027. doi:10.1002/cncr.10782<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/12209686/pubmed" id="12209686" target="_blank">12209686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30413383">
<a name="30413383"></a>Vergote I, Coens C, Nankivell M, et al; EORTC; MRC CHORUS study investigators. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncol</i>. 2018;19(12):1680-1687. doi:10.1016/S1470-2045(18)30566-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/30413383/pubmed" id="30413383" target="_blank">30413383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818904">
<a name="20818904"></a>Vergote I, Tropé CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. <i>N Engl J Med</i>. 2010;363(10):943-953. doi:10.1056/NEJMoa0908806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/20818904/pubmed" id="20818904" target="_blank">20818904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18453518">
<a name="18453518"></a>Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). <i>Ann Oncol</i>. 2008;19(9):1578-1583. doi:10.1093/annonc/mdn181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/18453518/pubmed" id="18453518" target="_blank">18453518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11812097">
<a name="11812097"></a>Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. <i>Gynecol Oncol</i>. 2002;84(2):335-338. doi:10.1006/gyno.2001.6527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/11812097/pubmed" id="11812097" target="_blank">11812097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1972736">
<a name="1972736"></a>Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. <i>J Clin Oncol</i>. 1990;8(7):1263-1268. doi:10.1200/JCO.1990.8.7.1263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/1972736/pubmed" id="1972736" target="_blank">1972736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25240821">
<a name="25240821"></a>Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncol</i>. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/25240821/pubmed" id="25240821" target="_blank">25240821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27502591">
<a name="27502591"></a>Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(28):3460-3473. doi:10.1200/JCO.2016.68.6907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/27502591/pubmed" id="27502591" target="_blank">27502591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16739353">
<a name="16739353"></a>Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. <i>Anticancer Res</i>. 2006;26(1B):777-782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/16739353/pubmed" id="16739353" target="_blank">16739353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17009648">
<a name="17009648"></a>Yokoyama Y, Futagami M, Higuchi T, Mizunuma H. Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. <i>Eur J Gynaecol Oncol.</i> 2006;27(4):437-439.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paclitaxel-conventional-drug-information/abstract-text/17009648/pubmed" id="17009648" target="_blank">17009648</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9735 Version 539.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
